Skip to content
Clinical Trials – home

Centre Hospitalier Universitaire De La Reunion

Verified siteinfo

France Allee Des Topazes, Cs 11021, 97400 St Denis, France

  • 11 trials recruiting
  • Systemic lupus erythematosus · Acute lymphocytic leukaemia · Acute myeloid leukaemia
  • Adults and children

About Specializations

Centre Hospitalier Universitaire De La Reunion in St Denis, France specialises in clinical trials of conditions such as Systemic lupus erythematosus, Acute lymphocytic leukaemia, Acute myeloid leukaemia, Anaplastic large cell lymphoma T- and null-cell types, and other specialisations. This site conducts important research.

Main research areas of the site

Systemic Lupus Erythematosus

The medical center is at the forefront of research in systemic lupus erythematosus, focusing on innovative therapies to reduce disease activity and improve patient outcomes.

  • Effectiveness of cenerimod
  • Long-term Safety and Tolerability

Through rigorous clinical trials, the center is advancing the understanding of lupus management, offering hope for improved quality of life for patients.

Lymphoma

Specializing in peripheral T-cell lymphoma and anaplastic large cell lymphoma, the center is pioneering treatments that aim to enhance progression-free survival and response rates.

  • Autologous Stem Cell Transplantation
  • Nivolumab for Relapsed/Refractory Cases

These studies are crucial in developing personalized treatment strategies that improve patient prognosis and survival rates.

Osteosarcoma

The center is dedicated to improving outcomes for patients with high-risk osteosarcoma through innovative treatment combinations.

  • Mifamurtide with Chemotherapy

By integrating new therapeutic agents, the center aims to enhance event-free survival and reduce relapse rates in affected individuals.

Renal Transplantation

Focusing on pediatric renal transplantation, the center is optimizing anticoagulation therapy to prevent vascular complications.

  • Enoxaparin Dose Adjustment

This research is pivotal in ensuring the long-term success of transplants and improving patient safety.

Syphilis

In the field of early syphilis treatment, the center is evaluating alternative antibiotic regimens to enhance cure rates.

  • Doxycycline vs. BPG

These efforts are aimed at providing more accessible and effective treatment options for patients worldwide.

Breast Cancer

Addressing breast cancer in young women, the center is exploring fertility preservation techniques alongside cancer treatment.

  • Oocyte/Embryo Cryopreservation

This research is vital for maintaining reproductive health and quality of life for young cancer survivors.

Neuroendocrine Cells Hyperplasia of Infancy

The center is investigating treatments for neuroendocrine cells hyperplasia of infancy to improve respiratory outcomes.

  • Methylprednisolone Pulses

These studies are essential for developing effective therapies for this rare pediatric condition.

Retinoblastoma

Focusing on retinoblastoma, the center is advancing conservative treatment strategies to preserve vision and control disease.

  • Intra-arterial Chemotherapy
  • Adjuvant Treatment Post-Enucleation

These efforts are crucial in improving visual outcomes and survival rates in affected children.

Cervical Cancer

In the realm of cervical cancer, the center is evaluating the efficacy of induction chemotherapy to enhance survival rates.

  • Concurrent Chemoradiotherapy

This research is pivotal in refining treatment protocols for advanced cases, aiming to improve patient outcomes.

Prostate Cancer

Specializing in prostate cancer with high-risk features, the center is exploring advanced therapeutic combinations to prevent relapse.

  • Darolutamide and Radiotherapy

These studies are instrumental in developing comprehensive treatment plans that enhance metastasis-free survival.

Vitiligo

The center is at the forefront of research in vitiligo, focusing on novel therapies to promote skin repigmentation.

  • SCENESSE® and NB-UVB Light Therapy

This research is essential in providing effective treatment options for individuals affected by this condition.

Renal Cell Carcinoma

In the field of metastatic renal cell carcinoma, the center is optimizing treatment regimens to improve survival outcomes.

  • Immune Checkpoint Inhibitors
  • VEGFR-Tyrosine Kinase Inhibitors

These efforts are crucial in advancing personalized medicine approaches for this challenging cancer type.

Cardiac Failure

Focusing on cardiac failure post-myocardial infarction, the center is evaluating therapies to improve cardiac function and remodeling.

  • Dapagliflozin Efficacy

This research is vital in enhancing recovery and quality of life for patients with heart failure.

Ependymoma

Specializing in ependymoma, the center is advancing diagnostic and treatment strategies to improve patient outcomes.

  • Centralized MRI Review
  • Post-Operative Chemotherapy

These studies are essential in refining therapeutic approaches for this complex brain tumor.

Lung Cancer

In the realm of non-small cell lung cancer, the center is exploring combination therapies to enhance treatment efficacy.

  • Platinum-Pemetrexed-Atezolizumab

This research is pivotal in developing targeted therapies for patients with specific genetic mutations.

Obesity

The center is investigating treatments for obesity related to genetic variants, focusing on weight management and metabolic health.

  • Setmelanotide Efficacy

This research is crucial in providing effective interventions for individuals with genetic predispositions to obesity.

Subarachnoid Hemorrhage

Specializing in subarachnoid hemorrhage, the center is evaluating therapies to prevent cerebral ischemia and improve recovery.

  • Milrinone Optimization

This research is vital in enhancing outcomes for patients with severe brain hemorrhages.

Respiratory Distress

The center is advancing strategies for respiratory distress management, focusing on optimizing emergency interventions.

  • Tracheal Intubation Optimization

This research is essential in improving patient safety and outcomes during critical care situations.

Acute Promyelocytic Leukemia

Focusing on acute promyelocytic leukemia in children and adolescents, the center is exploring combination therapies to enhance survival rates.

  • ATO and ATRA Combination

This research is crucial in developing effective treatment protocols for young patients with this aggressive leukemia.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Allee Des Topazes, Cs 1102197400 St DenisFrance
Recruiting now
11 trials
Conditions studied
21
Partner status
Verified site

More sites in St DenisFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Urethral valves

Recruiting

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study on the Effectiveness and Safety of Chikungunya Vaccine (VLA-1553) for People at Risk of Severe Chikungunya in La Réunion

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Centre Hospitalier Universitaire De La Reunion

Colon cancer+1

Recruiting

Study of CAPOX or FOLFOX chemotherapy before surgery in patients with obstructive colon cancer treated with colostomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centre Hospitalier Universitaire Rouen

HIV infection+1

Recruiting

Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Darunavir
  • Sponsor:Inserm

Nephroblastoma

Recruiting

Study on Metronomic Chemotherapy for Children and Teenagers with Relapsed or Refractory Wilms Tumor Using Vincristine, Irinotecan, Etoposide, Temozolomide, and Isotretinoin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Etoposide
  • Sponsor:Centre Oscar Lambret

Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Methylprednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Institut Gustave Roussy

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Pneumonia+1

Not yet recruiting

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospital Region Metz Thionville
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.